ClinicalTrials.gg
Status unknownNCT04452565NATADEXUpdated Feb 16, 2022

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

A Phase 2/3 interventional study of Drug: NA-831 and NA-831 and Atazanavir in Coronavirus Infection, Severe Acute Respiratory Infection and Severe Acute Respiratory Syndrome Coronavirus 2, sponsored by Biomed Industries, Inc.. Status unknown at 31 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by Biomed Industries, Inc. · Phase 2/3, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
525
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 401 studies in Coronavirus Infections with a site in United States — 29 open to participants now, 40 under way, 7 of them phase 3. Coronavirus Infections · United States.

Planned enrollment
57th of 283
525 · median 94
Started
2022
with 18 others
Phase 2/3
18 of 401
none open now
Registered
197th of 401
by date

Among the 401 studies in Coronavirus Infections with a site in United States, this one is the 57th largest by planned enrollment of the 283 interventional ones that give a count, is one of 19 that started in 2022, is one of 18 in phase 2/3, and was the 197th registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 51 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

29 of the 401 studies in Coronavirus Infections with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Coronavirus Infections studies recruiting now, 23 (59%) set no upper age limit and 9 (23%) stop at 75 or younger; 12 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Coronavirus Infections with a site in United States, or all of them as a file.
02

Study summary

This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.

Read the detailed description

The clinical Phase 2/3 evaluates the safety and efficacy of NA-831 alone, and a combination therapy comprises NA-831 with an anti-viral drug Atazanavir, NA-831 with an anti-inflammatory drug, Dexamethasone and a potential synergy between Atazanavir and Dexamethasone. NA-831 is also known as Traneurocin is a neuroprotective drug that is in clinical study for the treatment of Alzheimer's Disease. Participants will receive NA-831 or Atazanavir with or without Dexamethasone. Investigators are primarily interested in the time to recovery. In addition to study medications there will be daily symptom surveys for 14 days, then weekly thereafter for 3 weeks resulting in a total duration of follow up of 36 days. During hospitalization, daily symptom surveys will be carried out in conjunction with the study coordinators. Upon discharge participants will have the option to complete electronic symptom surveys or complete symptom surveys via telephone with the study coordinator. If electronic symptom surveys are selected on discharge participants will also receive a follow-up call from a study coordination every 7 days during the initial 14 day period. In addition, failure to submit a symptom survey will prompt a study follow up call.

03

Conditions studied

  • Coronavirus Infection
  • Severe Acute Respiratory Infection
  • Severe Acute Respiratory Syndrome Coronavirus 2

Keywords

  • NA-831
  • Atazanavir
  • Dexamethasone
  • COVID-19
  • Coronavirus Infection
  • Severe Acute Respiratory Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalization for management of SARS CoV-2 infection
  • Positive SARS CoV-2 test
  • Age > = 18 years
  • Provision of
  • (ECG) ≤ 48 hours prior to enrollment
  • Complete blood count, glucose-6 phosphate-dehydrogenase (G6PD), comprehensive metabolic panel and magnesium ≤ 48 hours prior to enrollment from standard of care.
  • If participating in sexual activity that could lead to pregnancy, individuals of who can become pregnant must agree to use throughout the study. At least one of the following must be used throughout the study:

    • Condom (male or female) with or without spermicide
    • Diaphragm or cervical cap with spermicide
    • Intrauterine device (IUD)
    • Hormone-based contraceptive

Exclusion criteria

Exclusion Criteria:

  • or allergy to NA-831, Atazanavir, Dexamethasone
  • Current use any antiviral drug or anti-inflammatory drug
  • Concurrent use of another agent
  • Invasive mechanical ventilation
  • Participants who have any severe and/or uncontrolled medical conditions such as:

    • unstable angina pectoris,
    • symptomatic congestive heart failure,
    • myocardial infarction,
    • cardiac arrhythmias or know prolonged > 470 males, > 480 female on
    • pulmonary insufficiency,
    • epilepsy (interaction with chloroquine),
  • Prior retinal eye disease
  • Concurrent requiring chemotherapy
  • Known Chronic Kidney disease, \< 10 or dialysis
  • G-6-PD deficiency, if unknown requires G6PD testing prior to enrollment

    • Known Porphyria
    • Known myasthenia gravis
    • Currently pregnant or planning on getting pregnant while on study
    • Breast feeding
    • /ALT > five times the ULN
    • > five times the ULN
    • Magnesium \< 1.4 mEq/L
    • Calcium \< 8.4 mg/dL > 10.6 mg/dL
    • Potassium \< 3.3 > 5.5 mEg/L
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
525 participants (estimated)

Study arms

  • Active comparator
    Active Comparator: NA-831 alone

    Arm 1: NA-831 30 mg orally twice a day for one day, followed by 30 mg once day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule

    Drug: Drug: NA-831

  • Active comparator
    Active Comparator: NA-831 plus Atazanavir Sulfate

    Arm 2: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule. AND Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets.

    Combination Product: NA-831 and Atazanavir

  • Active comparator
    Active Comparator: NA-83 plus Dexamethasone

    Active Comparator: NA-831 30 mg capsule plus Dexamethasone 4 mg Arm 3: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule. AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets.

    Combination Product: NA-831and Dexamethasone

  • Active comparator
    Active Comparator: Atazanavir and Dexamethasone

    Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets. AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets.

    Combination Product: Atazanavir and Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. 1. Time (Hours) to recovery

    Time (hours) from randomization to recovery defined as 1) absence of fever, as defined as at least 48 hours since last temperature ≥ 38.0°C without the use of fever-reducing medications AND 2) absence of symptoms of greater than mild severity for 24 hours AND 3) not requiring supplemental oxygen beyond pre-COVID baseline AND 4) freedom from mechanical ventilation or death

    Time frame: [ Time Frame: 36 days ]

Secondary outcomes

  1. Time fever resolution

    Time to resolution of fever defined as at least 48 hours since last temperature ≥ 38.0°C without the use of fever-reducing medications

    Time frame: [ Time Frame: 36 days ]

07

Study locations

25 of 31 sites recruiting
  • Coronavirus Research Institute- Testing Site
    Los Angeles, California 90095, United States
    Recruiting
  • Coronavirus Research Institute
    Orange, California 92868, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Palo Alto, California 94304, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Sacramento, California 95817, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    San Diego, California 92314, United States
    Recruiting
  • Coronavirus Research Testing Site
    San Francisco, California 94110, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Sunnyvale, California 94086, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Washington, District of Columbia 20007, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Washington, District of Columbia 20010, United States
    Not yet recruiting
  • Coronavirus Research Institute-Testing Site
    Fort Lauderdale, Florida 33308, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Tampa, Florida 33620, United States
    Recruiting
  • Coronavirus Research Institute- Testing Site
    Chicago, Illinois 60612, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Naperville, Illinois 60540, United States
    Not yet recruiting
  • Coronavirus Research Institute-Testing Site
    Baltimore, Maryland 21287, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Bethesda, Maryland 20892, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Boston, Massachusetts 02114, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Worcester, Massachusetts 01655, United States
    Not yet recruiting
  • Coronavirus Research Institute-Testing Site
    Ann Arbor, Michigan 48109, United States
    Not yet recruiting
  • Coronavirus Research Institute-Testing Site
    Detroit, Michigan 48202, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Newark, New Jersey 07102, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site-
    Bronx, New York 10467, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    New York, New York 10016, United States
    Recruiting
  • Coronavirus Research Institute- Testing Site
    Rochester, New York 14642, United States
    Not yet recruiting
  • Coronavirus Research Institute-Testing Site
    Durham, North Carolina 27704, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Coronavirus Research Institute- Testing Site
    Fort Sam Houston, Texas 78234, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Galveston, Texas 77555, United States
    Not yet recruiting
  • Coronavirus Research Institute-Testing Site
    Houston, Texas 77030, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Kirkland, Washington 98034, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Seattle, Washington 98104, United States
    Recruiting
  • Coronavirus Research Institute-Testing Site
    Tacoma, Washington 98431, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2022; primary completion for Dec 2023, 18 months later.

Of 32 phase 2/3 interventional studies under Coronavirus Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Jun 30, 2020
StartEst.
Jun 15, 2022
Primary completionEst.
Dec 15, 2023
CompletionEst.
Dec 15, 2023
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04452565
Lead sponsor
Biomed Industries, Inc.
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jun 15, 2022 (estimated)
Primary completion
Dec 15, 2023 (estimated)
Completion
Dec 15, 2023 (estimated)
Last update
Feb 16, 2022

Study contacts

Brian Tran, MD
Contact
BTran@biomedind.com
800-824-5135
Frank Kennedy, PhD
Contact
FKennedy@biomedind.com
800-824-5135
Lloyd Tran, PhD
study director · Biomed Industries, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion